Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones
Public ClinicalTrials.gov record NCT00576589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, 2-Part, Randomized, Subject And Investigator Blinded, Placebo-Controlled, Cross-Over Trial To Evaluate The Safety, Tolerability And Pharmacokinetics Of CE-326,597 In Obese, Adult Subjects With Asymptomatic Cholelithiasis
Study identification
- NCT ID
- NCT00576589
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Interventions
- CE-326,597 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Not listed
- Completion
- Aug 31, 2008
- Last update posted
- Jan 17, 2010
2008
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Anniston | Alabama | 36201 | — |
| Pfizer Investigational Site | Anniston | Alabama | 36207 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85013 | — |
| Pfizer Investigational Site | Anaheim | California | 92801 | — |
| Pfizer Investigational Site | DeLand | Florida | 32720 | — |
| Pfizer Investigational Site | Miami | Florida | 33143 | — |
| Pfizer Investigational Site | Orlando | Florida | 32809 | — |
| Pfizer Investigational Site | South Miami | Florida | 33143 | — |
| Pfizer Investigational Site | Honolulu | Hawaii | 96813 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67214 | — |
| Pfizer Investigational Site | Madisonville | Kentucky | 42431 | — |
| Pfizer Investigational Site | Willingboro | New Jersey | 08046 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00576589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2010 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00576589 live on ClinicalTrials.gov.